MedTrace Logo

Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

NCT00089570 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2017-10-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.

Conditions

  • Hepatorenal Syndrome

Interventions

DRUG

terlipressin

DRUG

Placebo

Sponsors & Collaborators

  • Mallinckrodt

    lead INDUSTRY

Principal Investigators

  • Arun J. Sanyal, M.D. · Medical College of Virginia, Virginia Commonwealth University Medical Center

  • Thomas D. Boyer, M.D. · University of Arizona Health Sciences Center

  • Peter Teuber, Ph.D. · Orphan Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-03-31
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089570 on ClinicalTrials.gov